Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_assertion type Assertion NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_head.
- NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_assertion description "[Tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) were previously the standard first-line treatments for lung cancers with activating EGFR mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_provenance.
- NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_assertion evidence source_evidence_literature NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_provenance.
- NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_assertion SIO_000772 26469914 NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_provenance.
- NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_assertion wasDerivedFrom befree-2016 NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_provenance.
- NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_assertion wasGeneratedBy ECO_0000203 NP1294990.RAPWq0QxyCSaJF6DwzH0q3pJ_HiMLqiFi6tT_5_4NDE04130_provenance.